The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women-Reference-Cited by-同舟云学术

The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women

Published:2020-09-14 Issue:11 Volume:43 Page:1133-1140
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Laker Eva Agnes Odongpiny^ORCID,Arinaitwe Arnold,Owarwo Noela,Onzia Annet,Nasasira Benson,Wailagala Abdullah,Kalule Ivan,Anguzu Godwin,Kiragga Agnes,Seden Kay,Lwanga Isaac,Castelnuovo Barbara,Musomba Rachel,Lamorde Mohammed

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-020-00974-9.pdf

Reference19 articles.

1. UNAIDS. UNAIDS data 2018. https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf. Accessed 05 Jul 2020.

2. WHO. Guidelines on the public health response to pretreatment HIV drug resistance. July 2017. https://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055-eng.pdf;jsessionid=C3EE93B78182C3FD322531B461143CBA?sequence=1. Accessed 01 Feb 2019.

3. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979–81.

4. WHO. Statement on dolutegravir. https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf. Accessed 01 Feb 2019.

5. Dodoo A, Hugman B. Risk perception and communication in sub-Saharan Africa. Drug Saf. 2012;35(11):1041–52.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study;BMC Infectious Diseases;2021-12

2. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda;BMC Infectious Diseases;2021-11-13

3. Lessons from dolutegravir and neural tube defects;The Lancet HIV;2021-01

4. Communication of teratogenicity risk with dolutegravir;Reactions Weekly;2020-10